Nasdaq:ALLR
Allarity Therapeutics, Inc.
A pre-revenue biotech firm investing heavily in R&D to develop next-generation oncology therapies while maintaining a cash runway funded by recent equity issuances.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock if they believe in the transformative potential of Allarity's proprietary platform to generate blockbuster oncology drugs with high market value. The recent capital raise provides a robust runway to advance multiple candidates into clinical trials, potentially validating the technology and setting up future commercial success. Early entry offers an opportunity to participate in significant upside before any potential product approvals or partnership deals materialize.
Bear Case
The stock is highly speculative given the total lack of revenue and a mounting retained earnings deficit of $119M, making it vulnerable to market downturns or funding gaps. Investors should avoid the stock if they cannot tolerate the risk of total capital loss in a pre-revenue company with no guaranteed path to profitability. The heavy reliance on equity financing suggests that without successful clinical outcomes, the company may struggle to maintain its current valuation.
About Allarity Therapeutics, Inc.
Allarity Therapeutics is a biotechnology company focused on discovering and developing novel therapeutic candidates, primarily targeting oncology and other serious diseases. The company operates within the specialized pharmaceutical research sector, leveraging its proprietary platform to advance early-stage drug programs toward clinical trials. With no current revenue from product sales, the firm relies entirely on financing activities to fund its extensive research and development expenditures.
Analysis
Management Discussion
Management has successfully secured substantial capital through financing activities totaling $36.8M, which offset a net cash outflow of $19.1M and maintained a healthy cash balance of $19.5M. Despite the significant operating loss driven by $27.2M in operating expenses and $6.1M in R&D spending, the company has preserved its liquidity position effectively for now. However, the deepening deficit and lack of product revenue indicate that the current financial model relies heavily on continuous external funding to sustain operations.
Industry Overview
The biotechnology industry is characterized by high failure rates in drug development and significant upfront costs for research and clinical trials before any commercial return is realized. Companies like Allarity operate in a competitive landscape dominated by large pharmaceutical firms and other biotech startups vying for advancements in oncology and rare diseases. Success in this sector requires substantial capital reserves and the ability to navigate complex regulatory pathways to bring novel therapies to market.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $34.5M | $17.1M | $27.2M |
| Operating Income | $-34.5M | $-17.1M | $-27.2M |
| R&D | $6.9M | $7.1M | $6.1M |
| G&A | $10.0M | $10.0M | $11.4M |
| Stock-Based Comp | $1.8M | $-71.0K | $71.0K |
| D&A | $60.0K | $37.0K | $9.0K |
| Other OpEx | $17.6M | $0 | $9.7M |
| Non-Operating Income | $0 | $5.3M | $2.3M |
| Interest Expense | $12.0K | $498.0K | — |
| Interest Income | $30.0K | $22.0K | $533.0K |
| Pre-Tax Income | $-34.5M | $-11.8M | $-24.9M |
| Income Tax | $-1.5M | $83.0K | $-381.0K |
| Continuing Ops | $-32.9M | $-11.9M | $-24.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-16.1M | $-11.9M | $-24.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-16.1M | $-11.9M | $-24.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $5.0M | $2.0M | $22.3M |
| Cash & Equivalents | — | $166.0K | $19.5M |
| Other Current Assets | — | $1.8M | $2.8M |
| Long-Term Assets | $9.6M | $9.9M | $309.0K |
| PP&E (Net) | $21.0K | $20.0K | $309.0K |
| Intangibles | $9.5M | — | $0 |
| Other LT Assets | $6.0K | $9.9M | $0 |
| Total Assets | $14.5M | $11.9M | $22.6M |
| Current Liabilities | $11.2M | $14.2M | $10.8M |
| Accounts Payable | $6.3M | $8.4M | $4.2M |
| Current Leases | $8.0K | — | — |
| Taxes Payable | $41.0K | — | — |
| Other Current Liab | $3.0M | $4.4M | $1.4M |
| Long-Term Liabilities | $1.4M | $446.0K | $0 |
| Total Liabilities | $12.7M | $14.6M | $10.8M |
| Shareholders' Equity | $1.9M | $-2.8M | $11.8M |
| Paid-In Capital | $83.2M | $90.4M | $131.1M |
| Retained Earnings | $-82.5M | $-94.5M | $-119.0M |
| AOCI | $-721.0K | $-411.0K | $-354.0K |
| Total L&E | $14.5M | $11.9M | $22.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-16.1M | $-11.9M | $-24.5M |
| Non-Cash Adjustments | $-3.8M | $-1.9M | $7.9M |
| Working Capital Changes | $3.1M | $1.1M | $-763.0K |
| Cash from Operations | $-16.8M | $-12.7M | $-17.4M |
| Capital Expenditures | $18.0K | — | $298.0K |
| Cash from Investing | $791.0K | $113.0K | $-298.0K |
| Cash from Financing | $-1.3M | $11.0M | $36.8M |
| FX Effect | $-189.0K | $-113.0K | $225.0K |
| Net Change in Cash | $-17.3M | $-1.8M | $19.1M |
| Beginning Cash | $19.6M | $2.0M | $166.0K |
| Ending Cash | $2.0M | $166.0K | $19.5M |
Frequently Asked Questions
How does Allarity Therapeutics, Inc. make money?
The company's operations are currently concentrated exclusively in drug discovery and development, with all financial activity directed toward advancing proprietary therapeutic candidates. Due to the lack of commercial revenue streams, there are no distinct geographic or product-based segments generating sales; instead, expenses are aggregated under general research and administrative functions.
What are the main risks for ALLR?
The company faces significant cash burn risks with a net loss of $24.5M in 2024, raising concerns about liquidity if new financing rounds are not successfully secured. Success is highly dependent on the ability of its drug candidates to advance through costly and uncertain clinical trials without guarantee of approval. The absence of commercial revenue makes the stock extremely volatile and sensitive to changes in interest rates or investor sentiment toward pre-revenue biotech. Potential dilution from equity issuances, evidenced by $37.4M raised recently, could negatively impact existing shareholders.
What is ALLR's competitive advantage?
Allarity utilizes a proprietary platform technology designed to enhance drug efficacy and selectivity, potentially reducing development timelines compared to traditional discovery methods. The company benefits from an experienced management team with deep expertise in oncology and the strategic partnerships that provide access to novel biological targets. Its lean operational structure allows for efficient allocation of capital toward high-potential early-stage assets.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.